1. Current Perspectives on the Management of Iron Deficiency in Chronic Heart Failure

2. Background

3. Program Overview

4. The Impact of Iron Deficiency in Chronic Heart Failure

5. ID vs Anemia in CHF

6. Prevalence of ID in Patients With CHF

7. ID Is Common Irrespective of Ethnicity, Sex, or Anemia Status

8. Causes of ID in CHF -- Absolute and Functional

9. Common Iron Deficit in Patients With CHF

10. Impact of ID in Patients With CHF

11. Impact of ID in Patients With CHF (cont)

12. ID Impairs Mitochondrial Function

13. Summary

14. Treating Iron Deficiency in Chronic Heart Failure

15. Correction of ID as a Therapeutic Target in HF

16. FAIR-HF: Study Design

17. FAIR-HF: Co-Primary Endpoints

18. FAIR-HF: 6MWT Secondary Endpoint

19. CONFIRM-HF: Study Design

20. CONFIRM-HF: Primary Endpoint

21. EFFECT-HF: Study Design

22. EFFECT-HF: Primary Endpoint Change in Peak VO2

23. Meta-Analysis: Time to First Event Outcomes

24. Oral Iron Replacement Does Not Work in HF

25. ESC Guidelines for the Diagnosis and Treatment of HF

26. Recent and Ongoing Trials in Iron Replacement Therapy

27. 4 Ongoing Large RCTs in Patients With HF

28. AFFIRM-AHF

29. FAIR-HF2

30. HEART-FID

31. IRONMAN

32. Potential Mechanism of Action of IV Iron

33. Effect of ID and Iron Supplementation on Cardiomyoctye Function

34. Summary

35. Iron Deficiency in Chronic Heart Failure Across the Spectrum of Ejection Fraction

36. Classification of HF According to EF

37. Prevalence of ID Across EF Spectrum of HF

38. ESC Recommendations Largely For HFrEF

39. Most Trial Data Based on Patients With HFrEF

40. Ongoing Trials With IV FCM in HF

41. Conclusion

42. Does Ejection Fraction Matter?

43. Diagnosing Patients With HFpEF

44. Managing Patients With HFpEF

45. Effect of ID on Patients With HFpEF

46. The Need for Trials on Patients With HFpEF and ID

47. FAIR-HFpEF Trial

48. FAIR-HFpEF Trial (cont)

49. Summary

50. Abbreviations

51. Abbreviations (cont)

52. Abbreviations (cont)